Pre-HIFU therapy tumor biopsy samples and post-HIFU resected tumor samples were processed within 20 min of excision. Resected tumor sections were evaluated by a board-certified pathologist (SCO) for definitive diagnosis, margin assessment, and identification of the ablated tissue. The treatment site and overlying skin were grossly evaluated prior to formalin fixation. Sections of the treated and untreated tumor were collected and microscopically evaluated. Sections of overlying skin were assessed microscopically when evidence of potential thermal injury was grossly visible. All sections for microscopy were routinely processed and stained with hematoxylin and eosin (H&E). Immunohistochemistry for CD3 (rabbit polyclonal, anti-human; A0452; Agilent/Dako, Santa Clara, California), IBA-1 (rabbit polyclonal, anti-human; NC9288364; Wako Chemicals, USA), and CD79a (mouse monoclonal, anti-human; sc-20064; Santa Cruz Biotechnology) was performed. All antibodies were validated and run on a Ventana Benchmark XP automated stainer (Roche Ventana, Oro Valley, Arizona) using the Discovery Universal secondary antibody (760-4205; Roche, Basel, Switzerland), ultraView Universal Alkaline Phosphatase Red Detection Kit (Roche), and hematoxylin counterstain. All antibodies were verified to work in canine tissue before use in research samples.
Nc9288364
Manufactured by Fujifilm
Sourced in United States
The NC9288364 is a laboratory equipment product manufactured by Fujifilm. It is designed to perform core functions within a laboratory environment. The detailed specifications and intended use of this product are not available for an unbiased, factual description.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using nc9288364
1
Histopathological Analysis of HIFU Therapy
2
Histopathological Analysis of HIFU Therapy
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Pre-HIFU therapy tumor biopsy samples and post-HIFU resected tumor samples were processed within 20 min of excision. Resected tumor sections were evaluated by a board-certified pathologist (SCO) for definitive diagnosis, margin assessment, and identification of the ablated tissue. The treatment site and overlying skin were grossly evaluated prior to formalin fixation. Sections of the treated and untreated tumor were collected and microscopically evaluated. Sections of overlying skin were assessed microscopically when evidence of potential thermal injury was grossly visible. All sections for microscopy were routinely processed and stained with hematoxylin and eosin (H&E). Immunohistochemistry for CD3 (rabbit polyclonal, anti-human; A0452; Agilent/Dako, Santa Clara, California), IBA-1 (rabbit polyclonal, anti-human; NC9288364; Wako Chemicals, USA), and CD79a (mouse monoclonal, anti-human; sc-20064; Santa Cruz Biotechnology) was performed. All antibodies were validated and run on a Ventana Benchmark XP automated stainer (Roche Ventana, Oro Valley, Arizona) using the Discovery Universal secondary antibody (760-4205; Roche, Basel, Switzerland), ultraView Universal Alkaline Phosphatase Red Detection Kit (Roche), and hematoxylin counterstain. All antibodies were verified to work in canine tissue before use in research samples.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!